Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232128 | 0.91 | FAAH (0.56) | FAAH | |
| SCHEMBL27718903 | 0.88 | FAAH (0.62) | FAAH | |
| SCHEMBL2234396 | 0.87 | HRH3 (0.73) | FAAH | |
| SCHEMBL2232921 | 0.86 | FAAH (0.58) | FAAH | |
| SCHEMBL2236459 | 0.86 | HRH3 (0.57) | FAAH | |
| SCHEMBL22346647 | 0.84 | HRH3 (0.56) | FAAH | |
| SCHEMBL2931705 | 0.84 | AKR1C3 (0.65) | FAAH | |
| SCHEMBL31277423 | 0.84 | HRH3 (0.56) | FAAH | |
| SCHEMBL4158729 | 0.84 | CA12 (0.60) | FAAH | |
| SCHEMBL2303680 | 0.84 | HRH3 (0.55) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102026975-A | Piperazines as anti-obesity agents | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| CN-101472907-B | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists | PF MEDICAMENT | 2012-08-29 | — | — | CN | disclosed |
| CN-102026975-A | Piperazines as anti-obesity agents | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | disclosed |
| CN-101472907-A | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists | PF MEDICAMENT (FR) | 2009-07-01 | — | — | CN | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | FAAH 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.